Metsera Inc. (NASDAQ:MTSR) Receives $55.75 Consensus Target Price from Analysts

Shares of Metsera Inc. (NASDAQ:MTSR) have earned an average rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $55.75.

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Metsera in a research report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Metsera in a report on Wednesday, October 8th. Leerink Partnrs downgraded Metsera from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 24th. Wells Fargo & Company lowered Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target on the stock. in a research report on Tuesday, September 30th. Finally, Bank of America raised their price target on Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 28th.

Metsera Price Performance

Shares of MTSR stock opened at $70.50 on Thursday. The stock’s fifty day simple moving average is $54.18 and its 200 day simple moving average is $39.58. Metsera has a one year low of $12.30 and a one year high of $83.86. The firm has a market cap of $7.42 billion and a price-to-earnings ratio of -11.16.

Metsera (NASDAQ:MTSR) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MTSR. Osaic Holdings Inc. lifted its position in Metsera by 45.5% during the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock worth $27,000 after buying an additional 296 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Metsera by 100.0% in the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after acquiring an additional 800 shares during the last quarter. Penserra Capital Management LLC bought a new position in shares of Metsera in the third quarter worth about $50,000. Strs Ohio acquired a new position in shares of Metsera during the first quarter worth approximately $76,000. Finally, Virtus Investment Advisers LLC bought a new stake in shares of Metsera during the second quarter valued at approximately $77,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.